Considering personalized Interferon-β therapy for COVID-19 - Sorbonne Université
Article Dans Une Revue Antimicrobial Agents and Chemotherapy Année : 2021

Considering personalized Interferon-β therapy for COVID-19

Résumé

Davoudi-Monfared et al. (1) report in this Journal the results from a clinical trial on COVID-19 patients showing that subcutaneous administration of interferon-β (IFN-β) was associated with a more rapid recovery from SARS-CoV-2 infection and decreased mortality.….
Fichier principal
Vignette du fichier
Antimicrobial Agents and Chemotherapy-2021-Dorgham-AAC.00065-21.full.pdf (524.65 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03138348 , version 2 (11-02-2021)
hal-03138348 , version 1 (19-09-2021)

Identifiants

Citer

Karim Dorgham, Avidan U Neumann, Maxens Decavele, Charles-Edouard Luyt, Hans Yssel, et al.. Considering personalized Interferon-β therapy for COVID-19. Antimicrobial Agents and Chemotherapy, 2021, ⟨10.1128/aac.00065-21⟩. ⟨hal-03138348v2⟩
170 Consultations
162 Téléchargements

Altmetric

Partager

More